Economics of Industry

It is estimated that one in three people born in 2015 in the UK may develop dementia, and clinical development success rates for dementia drugs are consistently lower than those for other therapy areas.

On Tuesday 6th October, James Anderson (GSK), Ri De Ridder (RIZIV-INAMI), and Sophia Tickell (Meteosan) will take part in an OHE seminar to discuss the Checklist for Collaborative, Mutually Acceptable Drug Pricing.

A Research Paper on the topic of incorporating life-cycle price modelling into pharmaceutical cost-effectiveness evaluations has just been published by OHE.

This article looks at how theory could be put into practice suggesting ways to implement a differential pricing system for branded medicines in the EU that can enhance overall welfare.

O'Neill, P. and Sussex, J.

Consulting Report
May 2015

The OHE undertook an analysis of the uptake of medicines in 13 high income countries. The UK perspective on this was published in November 2014 by the ABPI. OHE has been commissioned by LIF, the trade association of the pharmaceutical industry in Sweden, to reanalyse the international comparison of medicines uptake from the Swedish perspective; and the results are available here and on LIF’s website.

The business model for antibiotics is broken. We looked at other industries facing conceptually similar challenges - particularly when the incentive for R&D is delinked from the volume of sales.

It is surprisingly hard to measure how long medical research takes. A recently published study by OHE, Brunel and RAND Europe shows a better way to do that.

Recently published study by OHE, Brunel University, RAND Europe and Kings College London analyses time lags in medical research and where to shorten them.

Dr. Aslam Anis, Director of the Centre for Health Evaluation and Outcomes Sciences (CHEOS) in Canada will undertake a short sabbatical with the Office of Health Economics in February 2015.

Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis of how the US market may evolve.

Pages

Subscribe to RSS - Economics of Industry